Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NouvSoma001 in Ischemic Stroke
NCT06612710Phase 1Recruiting
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Lipid-based Nanoparticles, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in ischemic stroke comparing NouvSoma001 with Placebo (2 arms). Primary endpoint: Incidence and severity of all adverse events (AE) and serious adverse events (SAE) at 6 months. Started Nov 2025; status: recruiting.
02
Drugs
NouvSoma001
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06612710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06612710.